Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML

Cytarabine (Ara-C) is the first-line drug for the treatment of acute myelogenous leukemia (AML). However, resistance eventually develops, decreasing the efficacy of Ara-C in AML patients. The expression of SAMHD1, a deoxynucleoside triphosphate (dNTP) triphosphohydrolase, has been reported to be ele...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Feifei, Sun, Jun, Tang, Xiaofeng, Liang, Yiping, Jiao, Quanhui, Yu, Bo, Dai, Zhengzai, Yuan, Xuhui, Li, Jiayu, Yan, Jinhua, Zhang, Zhiping, Fan, Song, Wang, Min, Hu, Haiyan, Zhang, Changhua, Lv, Xiao-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270467/
https://www.ncbi.nlm.nih.gov/pubmed/35803902
http://dx.doi.org/10.1038/s41419-022-05023-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270467/
https://www.ncbi.nlm.nih.gov/pubmed/35803902
http://dx.doi.org/10.1038/s41419-022-05023-0

Ejemplares similares